| Literature DB >> 35692106 |
Bingshi Zhang1, Zeming Liu1, Sikai Liu1, Bo Liu1, Mengnan Li1, Wenao Li1, Yongtai Han1.
Abstract
BACKGROUND This study identified risk factors associated with reinfection and created a scoring system designed for patients with periprosthetic joint infection (PJI) who have undergone prosthetic resection and spacer implantation. MATERIAL AND METHODS Patients who underwent 2-stage revision for PJI from January 2010 to December 2017 were retrospectively analyzed in this study. Patients were divided into 2 groups: infection recurrence and infection cure. Demographic and clinical information, laboratory test results, and radiological images that were potentially associated with infection were obtained and analyzed. RESULTS Seven independent risk (protective) factors for infection recurrence in patients with PJI who underwent 2-stage hip revision surgery were identified: C-reactive protein level, type of bacterial infection, age, immunosuppression, albumin/globulin ratio, glucose level, and magnetic resonance imaging findings. Finally, a weighted scoring system of 100-mark system was established and the area under the curve was 0.965 (95% confidential interval=0.947-0.983). The predictive scores for low risk (≤30%), moderate risk (31-69%), and high risk (≥70%) of infection recurrence were ≤45, 46-77, and ≥78, respectively. CONCLUSIONS For patients with PJI who had already undergone joint resection and spacer implantation, this newly established scoring system might help determine the accurate risk of infection recurrence after a definitive new prosthesis implantation. Patients with scores greater than 78 points would be considered very likely to have an infection recurrence. Therefore, the second-stage revision surgery should be changed to an additional anti-infection treatment or a debridement surgery instead of a definitive prosthesis implantation surgery.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35692106 PMCID: PMC9205198 DOI: 10.12659/MSM.936973
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Demographic information of patients with periprosthetic joint infection undergoing 2-stage hip revision surgery.
| Patient characteristics | Infection recurrence (n=25) | Infection nonrecurrence (n=330) | Test statistics | P |
|---|---|---|---|---|
| Sex | ||||
| Male | 11 | 152 | 0.040 | 0.842 |
| Female | 14 | 178 | ||
| Age (years) | 65.17±19.84 | 62.43±17.81 | 0.682 | 0.007 |
| Body mass index (kg/m2) | 24.24±4.84 | 24.04±3.43 | 0.202 | 0.840 |
| Current smoker | ||||
| No | 22 | 296 | 0.072 | 0.789 |
| Yes | 3 | 34 | ||
| Current alcohol use | ||||
| No | 21 | 304 | 1.981 | 0.159 |
| Yes | 4 | 26 | ||
| Steroid use | ||||
| No | 17 | 254 | 1.035 | 0.309 |
| Yes | 8 | 76 | ||
| Diabetes | ||||
| No | 14 | 260 | 6.853 | 0.009 |
| Yes | 11 | 70 | ||
| Immunosuppression | ||||
| No | 12 | 233 | 5.554 | 0.018 |
| Yes | 13 | 97 | ||
| Rheumatism | ||||
| No | 19 | 297 | 4.658 | 0.031 |
| Yes | 6 | 33 | ||
| Type of implanted endoprosthesis | ||||
| Cemented prosthesis | 9 | 79 | 1.813 | 0.178 |
| Cementless prosthesis | 16 | 251 |
Mann-Whitney U test;
Chi-square test.
Results of hematological, bacteriological, and laboratory examinations of patients with periprosthetic joint infection undergoing 2-stage hip revision surgery.
| Patient characteristics | Infection recurrence (n=25) | Infection nonrecurrence (n=330) | P |
|---|---|---|---|
| CRP (mg/L) | 32.63±14.59 | 26.70±11.59 | 0.002 |
| Albumin (g/L) | 32.37±8.25 | 36.01±7.41 | 0.029 |
| Globulin (g/L) | 29.83±6.19 | 24.37±5.87 | 0.004 |
| Albumin/globulin | 1.12±0.29 | 1.49±0.36 | <0.001 |
| Glucose | |||
| <5.6 | 7 | 251 | <0.001 |
| 5.6–11.2 | 8 | 46 | |
| >11.2 | 10 | 33 | |
| Hemoglobin (g/L) | 119.56±19.31 | 121.72±17.68 | 0.827 |
| ESR (mm/min) | 52.54±11.53 | 50.71±16.37 | 0.392 |
| Fibrinogen (g/L) | 3.95±0.88 | 3.89±0.97 | 0.722 |
| D-dimer (mg/ml) | 0.91±0.37 | 0.86±0.32 | 0.109 |
| Platelet count | 341.70±99.65 | 327.23±85.82 | 0.510 |
| MRI findings | |||
| Negative findings | 2 | 157 | <0.001 |
| Only lamellated hyperintense synovitis | 8 | 73 | |
| Only soft tissue edema | 9 | 77 | |
| Lamellated hyperintense synovitis and soft tissue edema | 6 | 23 | |
| Allogeneic blood transfusion | |||
| No | 13 | 164 | 0.824 |
| Yes | 12 | 166 | |
| Infectious bacteria | |||
| Negative | 4 | 58 | <0.001 |
| G+ bacteria | 19 | 257 | |
| G− bacteria | 2 | 15 | |
| Antibiotic-resistant bacteria | |||
| Yes | 8 | 63 | 0.120 |
| No | 17 | 267 | |
| Antibiotics used regularly (≥3 weeks) | |||
| No | 6 | 77 | 0.939 |
| Yes | 19 | 253 | |
| Time of remission (days) | 28.04±10.36 | 26.14±11.95 | 0.602 |
| Spacer with antibiotics | |||
| No | 5 | 101 | 0.264 |
| Yes | 20 | 229 | |
| Time interval between prosthetic resection and hip revision (months) | 6.87±2.49 | 7.02±3.17 | 0.291 |
CRP – C-reactive protein; ESR – erythrocyte sedimentation rate.
Mann-Whitney U test;
Chi-square test.
Incidence, recurrence time, and characteristics of infection recurrence in patients with periprosthetic joint infection undergoing 2-stage hip revision surgery.
| Patient characteristics | Count | Proportion | Incidence (per 100 patients) |
|---|---|---|---|
| Incidence | |||
| Recurrence | 25 | 7.04% | 7.04 |
| Nonrecurrence | 330 | 92.96% | 92.96 |
| Total | 355 | 100.00% | – |
| Infection type | |||
| Deep infection | 19 | 76.00% | 5.35 |
| Superficial infection | 6 | 24.00% | 1.69 |
| Recurrence time | |||
| <1 m | 1 | 4.00% | 0.28 |
| 1–3 m | 8 | 32.00% | 2.25 |
| 3–6 m | 10 | 40.00% | 2.82 |
| 6–12 m | 5 | 20.00% | 1.41 |
| 12–24 m | 1 | 4.00% | 0.28 |
| Clinical manifestation | |||
| Sinus | 9 | 36.00% | 2.54 |
| Abscess | 7 | 28.00% | 1.97 |
| Both | 9 | 36.00% | 2.54 |
| Loosening of the prosthesis | |||
| No | 18 | 72.00% | 5.07 |
| Yes | 7 | 28.00% | 1.97 |
Independent risk factors for infection recurrence in patients with periprosthetic joint infection undergoing 2-stage hip revision surgery.
| Risk factors | HR | 95% CI for the HR | P |
|---|---|---|---|
| CRP | 1.059 | 1.012–1.185 | 0.002 |
| Bacterial infection | |||
| Negative | Ref. | ||
| G+ bacteria | 1.251 | 1.102–1.401 | 0.002 |
| G− bacteria | 2.165 | 1.452–3.022 | 0.032 |
| Age (years) | 1.085 | 1.053–1.201 | <0.001 |
| Immunosuppression | |||
| No | Ref. | ||
| Yes | 3.208 | 1.121–8.254 | <0.001 |
| Albumin/globulin | 0.928 | 0.875–0.945 | 0.020 |
| Glucose | 1.095 | 1.008–1.245 | 0.006 |
| MRI findings | |||
| Negative findings | Ref. | ||
| Lamellated hyperintense synovitis or soft tissue edema | 2.336 | 1.569–4.238 | <0.001 |
| Both | 3.980 | 2.250–6.233 | <0.001 |
Ref. – reference; HR – Hazard ratio; CI – confidential interval; CRP – C-reactive protein. Cox proportional hazards regression analysis was used to estimate these HRs, CIs, and P values. All potential risk factors (i.e., all variables reported in Tables 1 and 2) were initially included in the regression models. The stepwise regression method was used to determine the final independent variables in the equation. Variables with P>0.1 were removed from the equation.
Scoring system for predicting infection recurrence in patients with PJI undergoing 2-stage hip revision surgery.
| Risk factors | β-coefficient | Predictive score (total=100 points) |
|---|---|---|
| CRP | ||
| <30 mg/L | Ref. | 0 |
| 30–80 mg/L | 1.205 | 7.5 |
| >80 mg/L | 2.323 | 14.5 |
| Bacterial infection | ||
| Negative | Ref. | 0 |
| G+ bacteria | 1.195 | 7.5 |
| G− bacteria | 2.551 | 16 |
| Age (years) | ||
| <40 | Ref. | 0 |
| 40–70 | 0.852 | 5.5 |
| >70 | 1.875 | 12 |
| Immunosuppression | ||
| No | Ref. | 0 |
| Yes | 2.205 | 14 |
| Albumin/globulin | ||
| >2 | Ref. | 0 |
| 2–0.8 | 0.852 | 5.5 |
| <0.8 | 1.211 | 7.5 |
| Glucose | ||
| <5.6 | Ref. | 0 |
| 5.6–11.2 | 1.209 | 7.5 |
| >11.2 | 2.208 | 14 |
| MRI findings | ||
| Negative findings | Ref. | 0 |
| Lamellated hyperintense synovitis or soft tissue edema | 2.427 | 15 |
| Both | 3.501 | 22 |
Ref. – reference; CRP – C-reactive protein. The AUC of this scoring system was 0.965 (95% CI=0.947–0.983). The total score was the sum of the scores for each item. The predictive scores for a low risk (estimated incidence of infection recurrence ≤30%), moderate risk (estimated incidence of infection recurrence of 31–69%), and high risk (estimated incidence of infection recurrence ≥70%) of infection recurrence were ≤45 points, 46–77 points and ≥78 points, respectively.